Patients with hypomagnesemia, vasopressor requirements, or biomarkers indicative of neuroinflammation (e.g., elevated IL-6, MMP9) may derive greater benefit, whereas those with hypermagnesemia or advanced renal dysfunction require cautious dosing. Here, MMP9 is linked to Abnormal renal physiology.